Discontinued — last reported Q3 '22
Products & Services · Additional milestone payment
ADUHELM — Additional milestone payment
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ2 2020
Last reportedQ3 2022
How to read this metric
An increase indicates successful progress in clinical or regulatory milestones, while a decrease suggests fewer active development triggers or completed payment schedules.
Detailed definition
Reflects contingent payments made to third-party partners or licensors triggered by the achievement of specific clinical...
Peer comparison
Commonly found in pharmaceutical companies as 'milestone payments' or 'contingent consideration' within segment-level R&D or licensing expense disclosures.
Metric ID:
biib_segment_aduhelm_additional_milestone_paymentHistorical Data
4 periods
| Q2 '21 | Q3 '21 | Q2 '22 | Q3 '22 | |
|---|---|---|---|---|
| Value | $100.00M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | -100.0% | — | — |
| YoY Change | — | — | -100.0% | — |
Range$0.00 – $100.00M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's aduhelm — additional milestone payment?
- Biogen (BIIB) reported aduhelm — additional milestone payment of $0.00 in Q3 2022.
- What does aduhelm — additional milestone payment mean?
- Contractual payments triggered by reaching specific development or commercial goals for a product.